|Quantity Discounts||1 - 2|
|3 - 4|
|5 - 6|
|7 - 9|
|10 - 9999|
FDA Regulation of Regenerative Medicine: Risks and Opportunities in a Shifting Regulatory Environment
The regenerative medicine industry is rapidly growing and, with major court decisions, new and significant FDA guidance, and government enforcement actions, the regulatory landscape is more complex than ever.
This webinar CD and transcript identifies key trends and policies affecting the regenerative medicine industry in 2016 including:
Order today to gain a comprehensive understanding of the FDA’s current regulatory policies and enforcement trends affecting the regenerative medicine industry.
Meet Your Presenters
Andrew Ittleman, Esq., Founder and Partner, Fuerst Ittleman David & Joseph, PL
Andrew Ittleman exclusively represents clients in highly regulated industries, such as regenerative medicine and other FDA-regulated issues. Ittleman has been invited to speak at numerous conferences and panels on FDA enforcement issues, FDA regulation of stem cells and FDA regulation of off-label use. He also litigates extensively against the United States government in civil and criminal matters.
Kelly Lightfoot, Esq., Senior Associate, Fuerst Ittleman David & Joseph, PL
Kelly Lightfoot represents a variety of participants in the regenerative medicine industry, both public and private, including biologics manufacturers, clinical trial sponsors, medical device manufacturers, cryogenic banking facilities, medical tourism businesses, and physicians engaged in the development of autologous stem cell therapies.
Copyright ©2018. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing